BREAK-OUT GROUP 1 • COMMON BUILDING BLOCKS

11 June 2012 • 17:00 – 19.00

Co-chairs: Steffen Ernst & Bob Kavlock

Rapporteur: Troy Seidle

Objectives

1. Refine *Draft Recommendation for AOP-Oriented Funding Call(s)* with an eye to incorporating and building upon AXLR8-2 workshop recommendations/roadmap proposal and developments at EU, Member State, OECD and third country levels.
2. Identify most suitable (Horizon 2020) positioning, funding model(s) and tools for a research programme of this nature (i.e. strategically coordinated, public-private partnership with strong international collaboration).

Thought-starter questions

1. How should the *Draft Recommendation* document be refined in terms of:
    a. Science and technology building blocks?
    b. Ordering and timing of calls (e.g. make increasing amounts of funding available for key enabling technologies as AOP discovery efforts become more advanced, etc.)?
    c. Other?
2. What is the most suitable project model to ensure up-front coordination (i.e. gap analysis and targeted calls), effective and flexible management, and integrated, results-driven research?
    a. Management & scientific advisory structure established before calls are issued, determining R&D needs (awards grants/contracts) in a top-down approach?
    b. Coordination action attached to a research cluster (e.g. SEURAT-1 model)?
    c. Other?
3. What is the most suitable funding tool for a project of this type, i.e. grant agreement, contract, other?
4. What is the most suitable (Horizon 2020) funding stream(s), e.g.:
    a. Traditional Commission grant-based, bottom-up approach?
    b. Institutionalised PPP (e.g. IMI or Joint Technology Initiative)?
    c. PPP within the Health KIC (75% private funding within EIT framework)?
    d. Independent PPP established according to its own rules?
    e. Other?

BREAK-OUT GROUP 2 • SKIN SENSITISATION & IMMUNE DISORDERS

11 June 2012 • 17:00 – 19.00

Co-chairs: Joanna Jaworska & Nathalie Alépée

Rapporteur: Greet Schoeters

Objectives

1. Refine *Draft Recommendation for AOP-Oriented Funding Call(s)* in the context of sensitisation/immune disorders with an eye to incorporating and building upon AXLR8-2 workshop recommendations/roadmap proposal and developments at EU, Member State, OECD and third country levels.
2. Identify steps/priorities to bring skin sensitisation across the 'finish line'
3. Expand the OECD AOP with an eye to respiratory sensitisation.



Thought-starter questions

1. How should the *Draft Recommendation* document be refined in terms of:
   a. Science and technology building blocks?
   b. Ordering and timing of calls (e.g. make increasing amounts of funding available for key enabling technologies as AOP discovery efforts become more advanced, etc.)?
2. What additional steps are needed to achieve full replacement of animal testing for skin sensitisation and how should they be prioritised?
3. What are some apical / molecular anchors and key events in AOPs for respiratory sensitisation?

BREAK-OUT GROUP 3 • CANCER / CARCINOGENICITY

12 June 2012 • 17:00 – 19.00

Co-chairs: Mel Andersen & Jürgen Borlak

Rapporteurs: Hilda Witters, Kate Willett, Troy Seidle

Objectives

1. Refine *Draft Recommendation for AOP-Oriented Funding Call(s)* in the context of sensitisation/immune disorders with an eye to incorporating and building upon AXLR8-2 workshop recommendations/roadmap proposal and developments at EU, Member State, OECD and third country levels.
2. Begin to map out key carcinogenicity AOPs based on available expertise, including identification of key events and cell systems/omic approaches to test for perturbations, knowledge gaps, etc.



Thought-starter questions

1. How should the *Draft Recommendation* document be refined in terms of:
   a. Science and technology building blocks?
   b. Ordering and timing of calls (e.g. make increasing amounts of funding available for key enabling technologies as AOP discovery efforts become more advanced, etc.)?
2. What are some apical / molecular anchors and key events in AOPs for non-genotoxic carcinogenicity?

BREAK-OUT GROUP 4 • REPRODUCTIVE & DEVELOPMENTAL TOXICITY / DISORDERS

12 June 2012 • 17:00 – 19.00

Co-chairs: Robert Landsiedel & Tom Knudsen

Rapporteur: Horst Spielmann

Objectives

1. Refine *Draft Recommendation for AOP-Oriented Funding Call(s)* in the context of sensitisation/immune disorders with an eye to incorporating and building upon AXLR8-2 workshop recommendations/roadmap proposal and developments at EU, Member State, OECD and third country levels.
2. Begin to map out key reproductive and developmental toxicity AOPs based on available expertise, including identification of key events and cell systems/omic approaches to test for perturbations, knowledge gaps, etc.



Thought-starter questions

1. How should the *Draft Recommendation* document be refined in terms of:
   a. Science and technology building blocks?
   b. Ordering and timing of calls (e.g. make increasing amounts of funding available for key enabling technologies as AOP discovery efforts become more advanced, etc.)?
2. What are some apical / molecular anchors and key events in AOPs for reproductive and developmental toxicity?